Here is the latest news about Concerta generics, along with consumer tips for dealing with the shake-up following the FDA’s downgrading of two generics.
To recap, my previous post reported the FDA downgrading in November 2014 the two Concerta generics, manufactured by Mallinckrodt and Kudco/Kremers-Urban. It was determined that the medication in these products is released more slowly than with brand Concerta, thus creating an inferior response for people who otherwise did well on brand.
Optimal ADHD treatment calls for consistency of medication, and these generics had some folks all over the map. (My next post will be a curated compendium of their stories.)
These downgraded generics remain on the market—there are no safety issues per se—but no longer are pharmacies allowed to automatically substitute these downgraded generics for brand. For now.
More good news for regular Concerta users: The marketing deal between Janssen and Watson/Actavis, to distribute the brand as an authorized generic, has been extended through December, 2017.
More about the differences between “true” and “authorized” generics below. Read the rest of this entry »